Investors | Indegene

Company Overview

We help biopharmaceutical, emerging biotech and medical device companies develop products, get them to the market, and grow their impact through the life cycle in a more effective, efficient, and modern way. We bring together healthcare domain expertise, fit-for-purpose technology, and an agile operating model to provide a diverse range of solutions. These aim to deliver, amongst other outcomes, a personalized, scalable and omnichannel experience for patients and physicians. It’s what drives our team and our purpose to enable healthcare organizations to be future ready.

Company Announcements

FY26-27 Q1

Latest Quarterly Reports

Press Release

Analyst Call Transcripts

Investor Presentation

Financial Results

Q1 FY26-27 Quarterly Results

₹ 10,631 M

Revenue

39.7%

YoY Revenue Growth

₹ 1,162 M

PAT

-0.2%

YoY PAT Growth

Clients with $1 Mn+ Revenue

5,826

Total Employees

29.0%

Healthcare Expertise

46.9%

Women Employees

Being on the

RIGHT side of Gen-AI

E mbedded Revenue Partner

$77.1K

Revenue/Employee - Highest in Industry

Move from Content Generation to Revenue Orchestration
Become the Al Operating Layer for Commercial Teams
Shift Commercial Models to Outcome-Based Partnerships

D eep Domain Expertise

29% +

Employees From Healthcare

Capture, codify, and scale the Institutional knowledge enhancing every client engagement and making more consultative
Create a Living Pharma Knowledge Platform and a searchable knowledge assistant
Transform accumulated domain knowledge into proprietary Al platforms, playbooks, and accelerators that create a lasting competitive advantage.

G enAI Disruptor

10+

Revenue/Employee - Highest in Industry

Pharma companies face complexity explosion (content volume & regulatory compliance) & fragmented non-standardized models resulting in efforts to centralize operations
Our Al-enabled solutions engage at enterprise level (not brand-by-brand) to re-engineer & re-imagine end-to-end processes, thus accelerating this transformation & taking wallet share from incumbents
Genal price deflation pressures large incumbents but provides growth headroom for us at our current scale

E ngagement Model

-60%

Revenue/Employee - Highest in Industry

GenAl changes the economics of delivery- pricing around business outcomes instead of effort and FTEs.
Al-Powered Outcome Measurement- GenAl can continuously monitor leading indicators and quantify the impact of Indegene's interventions.
Embed Al into Client Workflows- accountable for improving those workflows-not just delivering projects.

Corporate Governance

Corporate Governance Policies Quarterly Compliance Report Other Documents CSR at Indegene Committees of the Board of Directors

Shareholder's Services

Distribution of Shareholding Related Party Transactions Annual General Meeting Postal Ballot

Quick Links